JMD ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naka, N.
Right arrow Articles by Itoh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naka, N.
Right arrow Articles by Itoh, K.
JMD 2005, Vol. 7, No. 2
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Quantification of SSX mRNA Expression in Human Bone and Soft Tissue Tumors Using Nucleic Acid Sequence-Based Amplification

Norifumi Naka*, Susumu Joyama{dagger}, Yoshitane Tsukamoto{ddagger}, Kiyoko Yoshioka{dagger}, Nobuyuki Hashimoto*, Takeshi Ujiiye§, Tsukasa Hayashi§, Masako Kawase§, Masayuki Mano, Shingo Ishiguro{ddagger}, Akira Myoui||, Takafumi Ueda||, Hideki Yoshikawa||, Nobuhito Araki* and Kazuyuki Itoh{dagger}

From the Departments of Orthopedic Surgery, * Biology, {dagger} and Pathology, {ddagger} Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; Kainos Laboratories, Incorporated, § Tokyo; the Department of Pathology, Osaka National Hospital, Osaka; and the Department of Orthopedic Surgery, || Osaka University Graduate School of Medicine, Osaka, Japan

The SSX family proteins have been considered new members of the cancer/testis antigens because of the restricted expression in testis among normal tissues and the activation in a wide range of cancers. Thus, they would be potential molecular targets for immunotherapeutic strategies. We have developed a competitive nucleic acid sequence-based amplification (NASBA) assay to analyze SSX mRNA expression in 211 bone and soft tissue tumors. The copy numbers of SSX mRNA per µg of total RNA in tumor tissues were widely distributed, ranging logarithmically from 0.6 to 6.6. We found that malignant tumors showed significantly higher expression of SSX mRNA than benign tumors (P < 0.0001). Further, SSX mRNA expression in stage III tumors was significantly higher than that in stage I or II tumors (P < 0.005). This NASBA assay was also more sensitive compared to immunohistochemistry using newly affinity-purified polyclonal antibody against SSX. Collectively, these results suggest that the SSX quantitative NASBA assay could provide useful information to select eligible patients for SSX-specific cancer vaccines.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology and the Association for Molecular Pathology.